CLOFAZIMINE, 50mg, soft caps.
STD
DORACLOF5C-
Valid Article
Account code:
60000
HS Code:
300490
Last Updated on:
22/10/2024, 12:20:19
Former
Code(s):
-X
6.2.4 - Antileprosy medicines
Classification of the medicines in groups and subgroups according to their therapeutic use.
The classification used by MSF is based on the WHO Model List of Essential Medicines.
6.2.5 - Antituberculosis medicines
Classification of the medicines in groups and subgroups according to their therapeutic use.
The classification used by MSF is based on the WHO Model List of Essential Medicines.
J04BA01
Anatomical Therapeutic Chemical Classification according to WHOCC
OC subscriptions: included in supply or field order tools (e.g. UniField)
|
|
SC subscriptions: included in supply or field tools
|
|
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)
|
|
CLOFAZIMINE
Therapeutic Action
Antileprotic and antituberculosis
Indications
Paucibacillary and multibacillary leprosy, in combination with rifampicin and dapsone
Drug-Resistant Tuberculosis (DR-TB), in combination with other TB medicines
Some restricted information has been hidden. Sign in
to see this information
Instructions for use
The 50 mg tablet and caps are intended for paediatric use.
Must be taken with food to improve gastrointestinal tolerance.
Protect the skin from sun.
Precautions for Use
May cause strong QT prolongation, orange-brown discolouration of skin and body fluids.
Storage
Below 25ºC - Protect from humidity